Eflepedocokin alfa
As of the edition of 20 October 2026, Eflepedocokin alfa is a protein: stopped in 2023; acts on IL10RB and IL22RA1.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Stopped, 2023
- Kind
- Protein
- Registered trials
- 4, 2 stopped early
- Disease areas
- Chemically induced; Digestive system; Infections; Lungs and airways
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Targets
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 2 | 4 | 2 | 0 | 2 |
| All trials | 4 |
Who ran its trials
| Company | Role | Years |
|---|---|---|
| EVIVE Biotechnology | Lead sponsor of trials | 2016 to now |